AP NEWS

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

September 26, 2018

INGELHEIM, Germany--(BUSINESS WIRE)--Sep 26, 2018--Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). The survey results will be presented today as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada.

The two most important treatment goals identified by those surveyed were increasing overall survival (OS) (77%), followed by quality of life (QoL) (69%), irrespective of the line of treatment.

Findings show that more than half (55%) of physicians strongly preferred a treatment sequence that offers patients the maximum time on targeted treatments. Furthermore, physicians reported that there is a strong need for information on potential treatment resistance mutations before changing their current treatment practice.

More information to make informed treatment decisions was needed depending on whether physicians preferred:

a first-line targeted treatment with the longest progression-free survival (PFS), or a first-line targeted treatment which offers the potential to use a different targeted therapy in second-line.

43% of those who preferred a treatment offering the longest PFS said they needed more information to make an informed treatment decision on the sequencing of targeted treatments compared to 23% of those who favour a first-line targeted treatment which offers the potential to use a targeted therapy in second-line.

Prof. Dr. Thomas Wehler PhD, Evangelisches Krankenhaus, Hamm, Germany, commented, “The results of this study show that physicians are unclear as to the best way to sequence targeted treatments in order to increase survival times, which is the main goal when selecting treatments for patients with EGFR mutation-positive NSCLC. More information and guidance around the impact of treatment sequencing on overall survival is required to support physicians when making treatment decisions.”

Dr. Victoria Zazulina, Global Head of Solid Tumour Oncology, Medicine at Boehringer Ingelheim, commented, “The availability of more treatment options means physicians now have the opportunity to sequence targeted treatments for EGFR mutation-positive NSCLC patients and consider the bigger picture from diagnosis. We undertook this research to learn what considerations guide physicians’ decisions to sequence targeted therapies, and this study unveiled the gap in clinical data that could clearly inform such decisions. Consequently, we embarked on a real-world evidence study evaluating the EGFR tyrosine kinase inhibitor (TKI) treatment sequence in patients with EGFR-mutant NSCLC, and are looking forward to sharing the outcomes with the physician community later this year.”

About the survey The Boehringer Ingelheim-sponsored survey evaluated 310 physicians (Oncologists, Pulmonologists, Respiratory Surgeons and Internal Respiratory Specialists) across four countries (China: 70, Germany: 70, Japan: 70 and USA: 100). The survey aimed to assess current attitudes towards decision making for TKI sequencing to determine what matters most when selecting a treatment and what challenges physicians face when initiating targeted treatment in EGFR M+ NSCLC patients.

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’:

For more information, please visit:  www.boehringer-ingelheim.com

Further Media Channels www.facebook.com/boehringeringelheim www.twitter.com/Boehringer www.youtube.com/user/boehringeringelheim

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005328/en/

CONTACT: Media Contact

Boehringer Ingelheim

Corporate Communications

Media + PR

Tetsu Owari

Phone: +49 6132 – 77 184867

Mobile: +49 (151) 14368601

Fax: +49 6132 – 77 6601

Email:press@boehringer-ingelheim.com

KEYWORD: EUROPE GERMANY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS ONCOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Boehringer Ingelheim

Copyright Business Wire 2018.

PUB: 09/26/2018 04:00 AM/DISC: 09/26/2018 04:01 AM

http://www.businesswire.com/news/home/20180926005328/en

AP RADIO
Update hourly